LataMed AI Corp. (OTC: LMED), a healthcare technology company focused on digital health and artificial intelligence solutions for Latin America, announced its participation in the Artificial Intelligence & Health Markets 2026 conference, scheduled for August 13-14, 2026, at Universidad Santa Maria in Caracas, Venezuela. The event, organized through its Venezuelan subsidiary LATAMEDAI VE, aims to bring together students, faculty, and professionals from systems engineering and healthcare disciplines to explore practical applications of AI and automation.
The company will be represented by Dr. Kevin Rodan Levy, CEO, and Carlos Pena, CFO. Their presentation will address the evolving role of AI in healthcare, systems engineering, digital infrastructure, and professional decision-making. LataMed AI intends to discuss how AI-supported tools may assist healthcare professionals with medical-data evaluation, clinical workflows, and operational decision-making, while also examining how automation can enhance the organization, reliability, and efficiency of technology systems in healthcare and other complex environments.
A key theme of the presentation will be the importance of maintaining qualified professional oversight when implementing AI. LataMed AI emphasizes that its technologies are designed to enhance human capabilities and support informed decision-making, not replace the independent judgment of healthcare professionals, engineers, or laboratory personnel. The conference will also cover topics such as integrating AI into existing systems, responsible data use, privacy and information security, operational risk management, and practical considerations for deploying technology in healthcare settings.
LataMed AI will also discuss the development of its healthcare technology ecosystem, including CardioAI, PulmoAI, and NeuroAI—AI-supported platforms intended to assist in cardiovascular, pulmonary, and neurological health information evaluation and management. These platforms remain subject to continued development, testing, regulatory requirements, and commercial implementation.
Dr. Levy commented, "Artificial Intelligence & Health Markets 2026 provides an important opportunity to engage directly with students, educators, and future professionals who will help shape the responsible use of artificial intelligence in healthcare and systems engineering. Our objective is to share practical perspectives on how intelligent technologies can support professional decision-making, improve digital workflows, and contribute to the continued development of healthcare infrastructure in Latin America."
The company believes that engagement with universities can increase awareness of emerging healthcare technologies, encourage responsible discussion about AI, and strengthen relationships with future professionals. Participation also offers LataMed AI insights into the perspectives of students, educators, researchers, and technical professionals as it continues developing solutions for the Latin American market.
This participation aligns with LataMed AI's broader strategy of supporting education, professional collaboration, and responsible adoption of digital healthcare infrastructure. The company intends to continue evaluating opportunities to participate in academic, healthcare, and technology forums that align with its objectives. Importantly, participation in the conference does not constitute an endorsement of LataMed AI or its technologies by Universidad Santa Maria, nor does it guarantee future collaborations or financial benefits.
For additional information, visit https://latamed.ai or review the company's filings with the U.S. Securities and Exchange Commission at www.sec.gov.
